09 April 2019

G 3/19 - Referral - Pepper

Referred point of law:
Under Article 112(1)(b) EPC the President of the European Patent Office refers the following points of law to the Enlarged Board of Appeal:

1. Having regard to Article 164(2) EPC, can the meaning and scope of Article 53 EPC be clarified in the Implementing Regulations to the EPC without this clarification being a priori limited by the interpretation of said Article given in an earlier decision of the Boards of Appeal or the Enlarged Board of Appeal?

2. If the answer to question 1 is yes, is the exclusion from patentability of plants and animals exclusively obtained by means of an essentially biological process pursuant to Rule 28(2) EPC in conformity with Article 53(b) EPC which neither explicitly excludes nor explicitly allows said subject-matter?

Analysis admissibility

  • The President submits that there are "different decisions" for question 1. In particular, T1063/18 would conflict with earlier decisions which would "acknowledge" that the AC is competent to give an authentic interpretation of an Article of the EPC in the Implementing Regulations "without being limited in this regard by an interpretation of the Article set forth in earlier case law". These decisions are T315/03 (r. 7.3) T272/95 (r.4), G2/07 (r.2.4). In para. 49 ff. the President further points to G2/06 (r.13), J 20/84 r.5 (about filing with fax) and T991/04 r.6). I note that none of these decisions appears to deal specifically with the issue of whether a decision of the Enlard Board has a limiting effect on subsequent changes of the Rules. 
  • The President submits that "On this basis question 2 is also admissible, since it is directly related to the different application of Article 164(2) EPC as exemplified in the specific case of Rule 28(2) EPC. In the alternative, question 2 should be considered admissible based on an analogous application of Article 112(1)(b) EPC". The President submits that application of Article 112(1)(b) by analogy is not excluded and that "[t]he effect of decision T 1063/18 is comparable to the situation where two Boards have given different decisions".
  • The President also submits as an auxiliary reason for admissibility of Question 2 that "question 1 is clearly admissible. Question 2 should be considered admissible too on the same basis." 
  • The President curiously enough cites G 2301/16 as support for the sentence that “the Enlarged Board of Appeal is ‘the highest judicial authority of the EPO’.” (para. 31 of the referral, footnote 29).  


EPO G 3/19 - G0003/19 - G 0003/19

https://www.epo.org/law-practice/case-law-appeals/eba/pending.html 



link to PDF: http://documents.epo.org/projects/babylon/eponet.nsf/0/7C42BAE688EAD1F1C12583D70036374E/$File/Referral%20T%201063%2018_for%20President_2%20April_edited_clean%20approved.hyperlinks.ohnebeck%20(2).pdf 



A. Admissibility of the referral


[...]
I. Different decisions of two Boards of Appeal
4. Decision T 1063/18 differs from earlier case law with regard to the way in which an EPC Rule which clarifies the meaning and scope of Article 53 EPC is assessed under Article 164(2) EPC.
8. This approach differs from other decisions, namely the case law relating to the implementation of Directive 98/44/EC of 6 July 1998 on the legal protection of biotechnological inventions (hereafter referred to as "EU Biotechnology Directive") into the EPC.


9. In decision T 315/03 (relating to what has become Rule 28(1)(d) EPC) the Board fully acknowledged the Administrative Council’s competence to interpret Article 53(a) EPC by amendment to the Implementing Regulations based on Article 33(1)(c) EPC without being limited in this regard by an interpretation of the Article set forth in earlier case law.


[...]
11. In decision T 272/95 (relating to what has become Rule 29(1) EPC) the Board, too, fully acknowledged the Administrative Council’s competence to give "a more detailed interpretation of the meaning of Article 53 EPC".4

12. In decision G 2/077 the Enlarged Board of Appeal also followed an approach under Article 164(2) EPC which differs from the one underlying decision T 1063/18 as well as decision T 39/93 on which the Technical Board of Appeal relied for its conclusion. Namely, the Enlarged Board of Appeal did not endorse the reasoning underlying decision T 39/93 that under Article 164(2) EPC a previous interpretation of Article 53 EPC by the Enlarged Board of Appeal would a priori preclude its clarification by means of a newly drafted Rule of the Implementing Regulations.


13. The Enlarged Board held in point 2.4 of the Reasons for the Decision that: "[b]ased on the assumptions that the approach to the interpretation of Article 53(b) EPC adopted by the boards of appeal prior to the introduction of Rule 23b(5) EPC 1973 reflected the true meaning of that Article, and that Rule 23b(5) EPC 1973 was aimed at a very narrow construction of Article 53(b) EPC 1973, and one which was hardly to be reconciled with the previous interpretation of that Article, the referring Board considers that Rule 23b(5) EPC 1973 is in conflict with Article 53(b) EPC 1973, contrary to Article 164(2) EPC.
Reference is made by the referring Board to decision T 39/93 (OJ EPO 1997, 134, point 2.3 of the Reasons), in which it was held that, in view of Article 164(2) EPC, the meaning of an Article of the EPC on its true interpretation as established - in that case - by a ruling of the Enlarged Board of Appeal cannot be overturned by a newly drafted rule of the Implementing Regulations. As will be set out below, this reasoning is based on assumptions which are not endorsed by the Enlarged Board, so that a problem of conflict between Rule 26(5) EPC and Article 53(b) EPC in the sense described by the referring Board does not arise. (emphasis added)." [emphasis in referral document]





T 0333/18 - Admissibility requests

Key points

  • In this examination appeal, the Board had to decide on the admissibility of auxiliary requests filed in response to the Board's communication.
  • The Board considers the amendments to introduce prima facie a lack of clarity. 
  • However, the Board then notes that: " the appellant argues that the requests were filed in reaction to objections raised by the board in its communication. However, this circumstance alone does not mean that a request filed in accordance with Article 13(1) RPBA has to be admitted (indeed, Article 13(1) RPBA makes no mention of any such criterion)." 
  • I wonder if the Board really means that the appellant does not have a right by filing a request (and having that request admitted) in case of new objections by the Board. In the end, Article 13(1) RPBA must yield to Article 113(1) EPC. However, the Board, in any case, finds that the same objection had been raised before by the Examining Division, so the point is moot. 
  • The timeline of the case is quite interesting. Entry into the European phase in 2010, supplementary ESR in 2015, first Communication also in 2015, summons in 2017, refusal decision 13.07.2017 issued in writing. Notice of appeal filed 11.09.2017; Statement of grounds filed 6.11.2017. Forwarding of the appeal by the Examining Division on 30.01.2018 (EPO Form 2701; signed by the 3 members of the Examining Division) (hence, no interlocutory revision under Article 109).  Which gives the appeal number ending with /18. Summons Board: 12.07.2018. Oral proceedings held on 24.01.2019 so within 1 year from receipt of the appeal. 


EPO T 0333/18 -  link

2. Auxiliary requests 1 to 3 - admissibility
2.1 These requests were filed in response to the board's communication. In accordance with Article 13(1) RPBA, whether or not they are taken into consideration is at the discretion of the board. In accordance with case law, a well-established criterion for determining whether to consider late-filed requests is whether or not they are prima facie allowable.
[...]
Consequently, by defining that optimisation occurs after each increase or decrease in the setting value, prima facie a lack of clarity has been introduced.
[...]

2.4 With respect to admissibility, the appellant argues that the requests were filed in reaction to objections raised by the board in its communication. However, this circumstance alone does not mean that a request filed in accordance with Article 13(1) RPBA has to be admitted (indeed, Article 13(1) RPBA makes no mention of any such criterion). Furthermore, in its decision (point 6), the examining division already noted a lack of clarity in claim 1 in respect of the wording "an optimization cycle that when complete begins another cycle optimizing said selected power transfer parameter until the next power transfer parameter is selected for optimization". Hence, amendments which re-define or clarify the concept of "optimisation" could have been submitted earlier, in particular with the filing of the statement of grounds of appeal. The appellant's argument is therefore unconvincing.

08 April 2019

T 0767/12 - Non-therapeutic use


Key points
  • In this examination appeal, independent claim 2 is direct to "Use of a composition comprising arachidonic acid ... for the non-therapeutic [...] promoting synchronisation of circadian rhythm". A circadian rhythm is a biological process displaying a 24 hour period. 
  • The Board: " the disclaimer in claim 2 of the main request at hand also introduces a lack of clarity, since the methods of the invention are necessarily therapeutic and their exclusion renders the scope of claim 2 void. This conclusion derives from the fact that desynchronisation of circadian or infradian rhythm causes symptoms which are generally recognised as being pathology-related and which produce at best discomfort." 
  • The Board: " Whether or not a symptom is of pathological nature cannot be established subjectively on the basis of the symptom intensity perceived by the patient. As the symptoms caused by biorhythm desynchronisation, such as sleep disorder, dizziness or headache, are generally recognised as being pathology-related, their treatment or prevention is necessarily therapeutic. The argument that the patient may be relieved from symptoms merely by resting cannot be accepted as a criterion for classifying a method as being non-therapeutic, since this is also a way of curing a cold, for instance, which is a clear pathological condition."
  • The appeal was forwarded to the Board in March 2012 and there was simply no action until 15.06.2018 (summons).
EPO T 0767/12 -  link


VI. With a letter of 4 December 2018, the appellant filed a new main request and auxiliary requests 1 to 4 to replace the previous ones.
Independent claims 1 and 2 of the main request read as follows:
"1. Use of triglyceride comprising arachidonic acid as a part of or all of the constituting fatty acids, or of methyl arachidonate or ethyl arachidonate, as active ingredient in the manufacture of a composition having a normalising action for infradian rhythm and/or a synchronisation promoting action for circadian rhythm, the composition being for therapeutic prevention or alleviation of biorhythm disorder caused by abnormality of infradian rhythm, or by retardation of synchronisation of circadian rhythm.
2. Use of a composition comprising as active ingredient triglyceride comprising arachidonic acid as a part of or all of the constituting fatty acids, or of methyl arachidonate or ethyl arachidonate, for non-therapeutic normalising of infradian rhythm and/or promoting synchronisation of circadian rhythm."

Reasons for the Decision
1. The appeal is admissible.
2. Main request
The disclaimer "non-therapeutic" in claim 2 of the main request was not disclosed in the application as originally filed. Accordingly, its allowability has to be examined in the light of decision G 1/03 (see also G 1/16, Reasons, point 43).
On this issue, the examining division held that it was not possible to distinguish between the therapeutic and non-therapeutic methods of the invention and hence the condition set out in G 1/03, Headnote, item 2.4, that the disclaimer must meet the requirements of clarity and conciseness (Article 84 EPC), was not fulfilled.
In the board's view, the disclaimer in claim 2 of the main request at hand also introduces a lack of clarity, since the methods of the invention are necessarily therapeutic and their exclusion renders the scope of claim 2 void. This conclusion derives from the fact that desynchronisation of circadian or infradian rhythm causes symptoms which are generally recognised as being pathology-related and which produce at best discomfort.
On this issue, the appellant argued that when the symptoms caused by biorhythm desynchronisation merely represent a transient nuisance, such as a slight sleep disorder removable by having some rest, they do not reflect a pathological state and their treatment cannot be considered to be therapeutic.
The board disagrees. Whether or not a symptom is of pathological nature cannot be established subjectively on the basis of the symptom intensity perceived by the patient. As the symptoms caused by biorhythm desynchronisation, such as sleep disorder, dizziness or headache, are generally recognised as being pathology-related, their treatment or prevention is necessarily therapeutic. The argument that the patient may be relieved from symptoms merely by resting cannot be accepted as a criterion for classifying a method as being non-therapeutic, since this is also a way of curing a cold, for instance, which is a clear pathological condition.
In addition, the appellant compared the methods in claim 2 with the treatment of fatigue discussed in the decision T 469/94. In that case, the board acknowledged that reducing the perception of fatigue in a person being about to participate in a major exercise or having completed a major exercise was non-therapeutic for two reasons: i) it was a transitory physiological condition caused by natural circumstances and removable by simple rest, in contraposition to situations where the person is relieved from pain or discomfort (see Reasons, point 4.2); and ii) non-therapeutic and therapeutic treatments could be separated because they involved different groups of persons (see Reasons, point 4.4).
In the board's view, the present case differs from the situation underlying T 469/94 in both of those essential aspects. Firstly, the symptoms treated with the alleged non-therapeutic method are not caused by natural circumstances but rather by an artificial shifting of natural rhythm which puts the person in a situation of at least discomfort and which provokes symptoms that are identified with pathologies, e.g. sleep disorder, dizziness, headache. Secondly, in view of the finding that the symptoms caused by biorhythm desynchronisation are necessarily therapeutic (see point 2, fourth paragraph above), the question of whether or not a therapeutic application can be separated from a non-therapeutic use does not arise.
Similarly to the case of T 469/94, the situations underlying decisions T 144/83 and T 584/88 are not applicable to the present case because in T 144/83 and T 584/88 the board could effectively distinguish between two groups of subjects: those suffering from being slightly overweight and those suffering from obesity (T 144/83), and those suffering from unhealthy snoring and those suffering from disturbing snoring (T 584/88).
In consequence, the disclaimer in claim 2 does not meet the requirements of Article 84 EPC and is therefore unallowable under G 1/03 (see Headnote, point 2.4) and G 1/16 (see Reasons, point 43).
[...]
3. Auxiliary request 1
[claim 2 is deleted]
3.1 Inventive step
The application [claim 1] is directed to the use of triglycerides containing arachidonic acid, methyl arachidonate or ethyl arachidonate as active ingredients for preventing or alleviating biorhythm disorders caused by abnormality of infradian rhythm or by retardation of synchronisation of circadian rhythm.
[...]
3.1.7 In conclusion, none of the cited documents or their combinations suggests the use of an arachidonic acid triglyceride, methyl arachidonate or ethyl arachidonate for the normalisation of biorhythm disorders. Hence, the subject-matter claimed in the only independent claim of auxiliary request 1 is inventive.
Order
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The case is remitted to the examining division with the order to grant a patent with the following claims and a description to be adapted thereto:
claims 1 to 15 of auxiliary request 1 filed during the oral proceedings of 13 December 2018.

05 April 2019

T 2435/13 - Crossing of plants

Key points

  • This examination appeal is about a method "for producing a B. oleracea plant " comprising a step of "crossing said B. rapa plant with a B. oleracea plant", i.e. crossing between different species. The applicant submits that this method is not excluded from patentability under Article 53(b) EPC because in claim 1 "only partial homologous recombination on limited portions of the respective genomes took place". Therefore, "the claimed method was not directed to a process for the production of plants involving sexually crossing the whole genomes of plants" as specified in G2/07 and G1/08. G2/07 and G1/08 referred to conventional method "based on the sexual crossing of plants (i.e. of their whole genomes)" as being excluded. The present Board has to interpret the "i.e." phrase.
  • "The board considers that, in fact, it can rather be inferred from [G2/07 and G1/08] that the EBA considered all methods containing or consisting of steps of sexually crossing the whole genome of plants and the subsequent selection of plants, regardless of those plants being sexually incompatible or not, to be excluded from patentability. In the board's view this is so since it was decisive for the EBA that in such processes, in contrast to other processes to change the genome of plants, such as e.g. irradiation [...], the genetic make-up of the plants resulting from the cross is determined by the result of the meiosis in the parent plants." 



T 2435/13 - link

Claim 1 of the main request read:
"1. A method for producing a B. oleracea plant comprising a monogenic and dominant resistance to clubroot comprising the steps of:
a) obtaining a B. rapa plant resistant to clubroot comprising a monogenic and dominant resistance to clubroot;
b) crossing said B. rapa plant with a B. oleracea plant,
c) rescuing embryos resulting from the cross of step b);
d) regenerating a plant from a embryo of step c);
e) selecting a plant of step d) that is resistant to clubroot comprising a monogenic and dominant resistance to clubroot;
f) back-crossing a plant resulting from step e) with a B. oleracea plant;
g) rescuing embryos resulting from the back-cross of step f); and
h) selecting a plant of step g) that is resistant to clubroot comprising a monogenic and dominant resistance to clubroot."

Reasons for the Decision
1. The appeal is admissible.
Introduction - The invention described in the application
2. Disclosed in the application (see e.g. page 2, lines 6 to 15, page 10, line 5 to page 11, line 2, example 1) is the transfer of a monogenic dominant resistance to clubroot from Chinese cabbage (Brassica rapa) to initially broccoli (B. oleracea) and then further to other B. oleracea cole-crop forms such as white cabbage, cauliflower and Brussels sprouts.
3. The resistance to clubroot was transferred from B. rapa to B. oleracea by means of an interspecific cross (hybridisation) followed by embryo rescue of the hybrid F1 progeny. Clubroot-resistant F1 progeny plants were then used for repeated backcrossing to B. oleracea and disease tests in all backcross generations. Plants resulting from the first backcross (BC1 progeny) were also recovered by embryo rescuing.
4. Embryo rescue - which techniques as such were known in the art - to obtain the F1 (and BC1) progeny after the interspecific cross is necessary in order to overcome the sexual incompatibility between B. rapa and B. oleracea due to the different number of chromosomes (n=10 or 9, respectively) in the two species. Embryo rescue in fact allows the problems of the non-viability of the embryo due to degradation of the endosperm in the seeds comprising the F1 embryos (10 + 9 chromosomes) to be overcome.

04 April 2019

T 2699/17 - No surgical method

Key points

  • Claim 1 directed to a method of "the guided expansion of an elastomeric material within the sulcus of a tooth" (for the term sulcus, see wiki). "In this way, the gingiva is retracted from the tooth, such that an appropriate impression of the tooth may be obtained, which is then used in the manufacture of the crown restoration". The question is if this is a surgical method under G1/07. "G1/07 found that it "appeared hardly still justified to exclude from patentability certain, albeit invasive techniques, at least when performed on uncritical parts of the body", which were carried out in a non-medical, commercial environment like in cosmetic salons and in beauty parlours". This was said to apply "as a rule to treatments such as tattooing, piercing, hair removal by optical radiation, micro abrasion of the skin" [i.e., these are allowable].
  • The Board first identifies the health risk: "minor injury of the epithelium may occur, which may also lead to bleeding (in particular with inflamed or pre-damaged tissue)". The Board then has to establish if this risk is a substantial health risk within the meaning of G1/07. The Board follows the "more abstract criterion" of T1695/07 as it "provides for a practical and feasible assessment of the health risk involved". Hence, an analysis of relative risk is not required. Rather, "the assessment should be limited to a more abstract basis, i.e. to the question "Is a certain health risk present?" and "Is it substantial?"."
  • The Board then finds the risk involved to be similar to those of piercing and microabrasion, which are allowable under G1/07. Therefore, the method of the invention does not involve a substantial health risk.
  • The body part is not critical, no significant medical expertise is required. 
  • Finally, about the "freedom of the medical profession": " Moreover, sulcus retraction is one step in the preparation of an impression which is subsequently used e.g. for the manufacture of a dental crown. In other words, it belongs to the context of manufacturing a dental implant and is thus not at the core of the dental practitioner's freedom to choose the best treatment for the patient, which is rather in deciding that the patient needs a crown, to prepare the tooth accordingly, and to apply the crown. There is thus no need to exclude the claimed method to guarantee the freedom of the medical profession to apply the treatment of choice." 
  • The 12 years first instance examination (from 2005) is no substantial procedural violation because no PACE request was filed and because G1/07 was issued meanwhile.
  • The case is remitted for novelty and inventive step.


  • Update 23.04.2020: the reasoning about Art.53(c) was followed in T 0467/18 which was also about sulcus retraction. “Angesichts der vorgelegten Nachweise ist die Kammer der Ansicht, dass die beanspruchte Verwendung lediglich einen minimal invasiven Schritt aufweist, der keinen erheblichen physischen Eingriff am Körper darstellt und dessen Durchführung nicht mit einem wesentlichen Gesundheitsrisiko verbunden ist.”


EPO T 2699/17 - link



V. The independent process claims of the main request read as follows:
Claim 1:
"A process of retraction of sulcus (3), comprising the steps of:
i. applying an elastomeric material, preferably a silicone material (4), a polyurethane material and/or a polyether material onto and/or at the vicinity of the boundary of a tooth (1) and adjacent gingiva (2) and/or sulcus (3), which elastomeric material (4) expands during or after its curing reaction;
ii. applying a cap (6) onto said tooth (1), thereby forming a chamber over said elastomeric material (4), wherein said chamber comprises as its walls the tooth (1), the cap (6) and an outer section (2a) of said gingiva (2);
whereby said chamber allows for the elastomeric material (4) to expand into the sulcus (3), characterized in that
- said cap (6) is at least partially filled with a plastically deformable, especially malleable material (7) when applied onto said tooth (1) in step ii.;
and/or that said cap (6) is deformable, especially under biting pressure."


Reasons for the Decision
1. Article 53(c)
1.1 According to Article 53(c) EPC, European patents "shall not be granted in respect of ... methods for treatment of the human or animal body by surgery ... ".
The criteria of decision G 1/07 (OJ EPO 2011, 134)
Following decision G 1/07, the methods excluded from patentability pursuant to Article 53(c) EPC as methods for treatment of the human or animal body by surgery are methods in which maintaining the life and health of the subject is important and which comprise or encompass an invasive step representing a substantial physical intervention on the body which requires professional medical expertise to be carried out and which entails a substantial health risk even when carried out with the required professional care and expertise.
As summarised in T 1695/07, point 6.3 of the reasons, G 1/07 advocates for a "narrower understanding" of what constitutes by its nature a "treatment by surgery" within the meaning of Article 53(c) EPC, which ruled out from the scope of the application of the exclusion clause "uncritical methods involving only a minor intervention and no substantial health risks, when carried out with the required care and skill, while still adequately protecting the medical profession". In particular, G 1/07 found that it "appeared hardly still justified to exclude from patentability certain, albeit invasive techniques, at least when performed on uncritical parts of the body", which were carried out in a non-medical, commercial environment like in cosmetic salons and in beauty parlours". This was said to apply "as a rule to treatments such as tattooing, piercing, hair removal by optical radiation, micro abrasion of the skin".
On the other hand, the "definition of the term "treatment by surgery" must cover the kind of interventions which represent the core of the medical profession's activities, i.e. the kind of interventions for which their members are specifically trained and for which they assume a particular responsibility". These physical interventions on the body were defined as those which "require professional medical skills to be carried out and which involve health risks even when carried out with the required medical professional care and expertise".
In the following, these criteria defined in G 1/07 are applied to the specific method claimed.
The invention
1.2 The present application relates to the guided expansion of an elastomeric material within the sulcus of a tooth. In this way, the gingiva is retracted from the tooth, such that an appropriate impression of the tooth may be obtained, which is then used in the manufacture of the crown restoration.
1.3 Anatomically, the gingival sulcus lies between the enamel of the tooth and the gingiva. On the gingival side, the surface is covered by the sulcular epithelium (which sits on a basal membrane). The sulcus forms a "pocket" (such pockets markedly increase in size in periodontal disease). At its bottom, the epithelium comes into contact with the cementum (junctional epithelium), even further caudal, the gingival/periodontal fibres anchor the tooth root to the bone and the gingiva.
The health risk involved
1.4 Sulcus retraction widens the sulcus by different techniques, some of which (mechanochemical = insertion of impregnated cord, purely mechanical, electrosurgical) have been associated with necrosis and/or stripping of the gingival sulcus, permanent periodontal damage and even bone loss (see e.g. document A.2.4, Introduction, page 2, 3rd para). Necrosis, permanent periodontal damage and bone loss would appear to qualify as substantial health risks.
1.5 However, with regard to sulcus retraction by so-called "retraction pastes", the evidence provided by the appellant points to a considerably minor health risk. This is true, in particular, for "Magic Foam Cord", which is an expanding polyvinyl siloxane material (see document A2.5, page 1054, left-hand column, "cordless techniques", line 27 ff), i.e. a material falling under the definition of claim 1.
Document A2.5 reports on a study in which healthy subjects were tested (see Material and Methods, first paragraph). For Magic Foam Cord, the probing depth (measured essentially by carefully inserting a probe into the pockets) remained almost the same at baseline, 1 and 7 days respectively (see Table 3 and "results, page 1056, left-hand column, lines 6-9). This indicates that the periodontal attachment fibres were not violated. The gingival index (an index for gingiva irritation and inflammation) increased after the retraction, but after seven days decreased to a non-significant level compared with the baseline measurements (Table 3, page 1056, the passage bridging the middle and right columns). No bleeding occurred with the cordless techniques (page 1056, right-hand column, second paragraph).
1.6 The study underlying document A2.4 investigated the effect of retraction material on gingival health using histopathological means (in this case the subject did not have healthy teeth but teeth which needed to be extracted, although still without periodontal disease; see "Conclusion, Future research"). Magic Foam Cord was found to respect the periodontium (Abstract, "Conclusion", last sentence). In most cases, even the junctional epithelium was found to remain intact ("Discussion", penultimate paragraph).
1.7 These clinical findings are in accordance with Magic Foam Paste exhibiting only a mild pressure of 32.8 kPa
(document A2.3, Abstract, Results), which is far below the 2 400 kPa found by Van der Velden to allow a probe tip to reach the bottom of the sulcus while maintaining an intact coronal connective tissue (A2.3, page 164, left-hand column, lines 2-9; see also Van der Velden's study A2.2).
1.8 The clinical/scientific evidence provided thus supports the statement by Mr Dumfahrt and Mrs Steinmassl (A2.1, last paragraph), according to which Magic Foam Cord is a gentle gingival retraction means which does not disrupt the gingival basal membrane.
1.9 To conclude, the periodontal connective tissue remains intact and minor injury of the epithelium may occur, which may also lead to bleeding (in particular with inflamed or pre-damaged tissue). If the epithelium is damaged, bacteria may invade, thereby causing inflammation. However, both bleeding and inflammation were found to rapidly heal.
1.10 While the evidence provided applies to a particular paste (Magic Foam Cord), in view of the pressure determined by Van der Velden (A2.2) and the pressures measured in (A2.3) there is a broad "safety margin", such that extrapolation of the experimental data to the other pastes falling under the claim is justified.
Does the method qualify as "substantial physical intervention on the body", i.e. is the health risk a substantial health risk within the meaning of G 1/07?
1.11 After establishing the health risk involved, it has to be decided whether that health risk qualifies as substantial within the meaning of G 1/07, i.e. whether the risk goes beyond the side effects of piercing, hair removal by optical radiation, or microabrasion of the skin.
For that evaluation, different approaches have been suggested in case law, namely, the 'risk matrix' in decision T 663/02 and a 'more abstract risk criterion' in decision T 1695/07 (see point 12.2.4 of the reasons).
In the present decision essentially, the 'more abstract risk criterion' approach is followed, which in the view of the present Board provides for a practical and feasible assessment of the health risk involved.
As to the appellant's concerns regarding T 1695/07 allegedly advocating - according to point 12.2.2 of its reasons - an evaluation of the individual health risk of the individual patient and judging the health risk in relation to the potential benefit to be achieved by the intervention, the Board notes the following: In decision T 1695/07, point 12.2 of the reasons explains why Board 3.3.07 considers that G 1/07 cannot be understood as requiring a factual risk analysis based on objective evidence, such as performed in T 663/02 ("risk matrix"). Its arguments in this respect are discussed in points 12.2.1 and 12.2.2 of the reasons (i.e. in the passage the appellant is concerned about). Point 12.2.1 essentially states that already for an "absolute scale" risk analysis, significant and reliable data are not normally available. As discussed in point 12.2.2, the situation is even worse with respect to the relative risk of a specific patient, i.e. when trying to draw up an individualised risk matrix for the particular patient concerned. From these arguments the Board then concludes (point 12.2.3 of the reasons) that "an objective and concrete analysis of the absolute or relative risks, which is hardly feasible, cannot have been intended by the Enlarged Board of Appeal and should therefore not be required".
Indeed, T 1695/07 does not advocate the analysis of a relative risk. The appellant's concerns in this respect are unfounded. Instead, see T 1695/07, point 12.2.4 of the reasons, the assessment should be limited to a more abstract basis, i.e. to the question "Is a certain health risk present?" and "Is it substantial?".
The present Board joins the concerns of Board 3.3.07 with respect to the practical feasibility of the "risk matrix" approach of T 663/02, which consequently is not applied to the present case.
With respect to the appellant's argument that by a malicious choice of the patient, a considerable (individual) health risk could be provoked for basically every method, the following is noted: G 1/07 talks about a "substantial health risk even when carried out with the required professional care and expertise". This wording excludes considering as substantial those health risks which only occur in patients for which the method in question is clearly contraindicated, such that their execution on the respective patient would have to be seen as going against the required professional care and expertise.
1.12 Superficial bleeding and superficial germ invasion are typical risks associated with procedures such as piercing or microabrasion of the skin. Such bleeding can usually be easily controlled (either it stops spontaneously or by simple application of external pressure). Likewise, the superficial infection is usually overcome by the body's immune system.
The Board is of the opinion that the risks established above (see point 1.8) for the claimed method are at a level with those present in methods which G 1/07 considered not to involve a substantial health risk.
Thus, the claimed method does not comprise or encompass an invasive step representing a substantial physical intervention on the body and does not entail a substantial health risk in the sense of G 1/07.
Criticality of the body part
1.13 Furthermore, with the deeper tissue, i.e. the periodontal connective tissue, remaining intact (see point 1.9 above), and the possible damage being limited to the superficial epithelium, the claimed method qualifies as a method of a low degree of intervention being applied to uncritical parts of the body in the sense of G 1/07.
Medical expertise/specific training required?
1.14 The cap is held in place by the patient's counter bite, with the retraction being essentially self-regulated through the pressure developed in the curing material. Moreover, during curing the actual degree of sulcus retraction cannot be judged because the site is covered by the cup and the retraction paste.
Thus, the specific training necessary for performing the method is minimal, as is the medical expertise required from the person applying the method. With the process being essentially self-regulated, the person performing the method, furthermore, does not assume a particular responsibility therefore.
Intervention representing the core of the medical profession's activity
1.15 Moreover, sulcus retraction is one step in the preparation of an impression which is subsequently used e.g. for the manufacture of a dental crown. In other words, it belongs to the context of manufacturing a dental implant and is thus not at the core of the dental practitioner's freedom to choose the best treatment for the patient, which is rather in deciding that the patient needs a crown, to prepare the tooth accordingly, and to apply the crown. There is thus no need to exclude the claimed method to guarantee the freedom of the medical profession to apply the treatment of choice.
1.16 In conclusion, the Board is of the opinion that the method according to claims 1 and 2 does not fall under the exception defined in Article 53(c) EPC.
2. Alleged substantial procedural violation
2.1 Duration of the proceedings
The application was filed in February 2005 and the decision to refuse the application was issued in September 2017, which amounts to a total processing time of more than 12 years. The Board agrees that this is by far above the average duration of an examination procedure.
In decision T 2707/16 (cited by the appellant) Board 3.5.07 held that an excessive duration of proceedings may amount to a substantial procedural violation. Without entering in the discussion whether this view is fundamentally correct (see in this respect the discussion under point 17 of the reasons), T2707/16 states under points 29 and 30, that the reasonableness of the length of the proceedings must be assessed in each case according to the particular circumstances, taking into account among others the factual, procedural and legal complexity of the case.
As also conceded by the appellant, in the present case there was no single unacceptably excessive delay, such as the long period of stagnation in case T2707/16. Instead, the examining division regularly returned to the case and addressed various issues of substance, which the appellant promptly addressed.
Furthermore, during the prosecution of the case, Enlarged Board of Appeal decision G1/07 was issued which was highly pertinent particularly with respect to the objection under Article 53(c) EPC. The Board is of the opinion that taking into account said decision and in particular the case law which only evolved in the years after its issuance explains and justifies to some extent the delays in the present case (and possibly the division's "see-saw reasoning"/"change of mind" which the appellant complains about; see below).
Moreover, the Office offers appellants the opportunity via the so-called PACE programme (see e.g. the Guidelines E-VIII, 4) to accelerate the proceedings. By decision of the President dated 12 July 2007 (Special edition No. 3, OJ EPO 2007, J.3), such requests are not published and are excluded from file inspection.
The Board cannot see why the appellant, who apparently was aware of but not satisfied with (in its view) the too slow but regular pace of the proceedings, waited until the appeal stage to voice its concerns instead of making use of the PACE programme, which gives applicants a convenient tool to speed up the pace at which the proceedings are progressing.
To conclude, taking into account the particular circumstances of the case, the Board comes to the conclusion that although undesirably long, the duration of the case does not amount to a substantial procedural violation.
2.2 "See-saw" reasoning
The messages that the appellant received from the EPO in this case were uncontestedly inconsistent.
However, the statement that bleeding was of no relevance originated from a person who was never part of the examining division. For that reason alone, the fact that this statement was not followed later on cannot result in a procedural error by the division.
With respect to the communication dated 22 August 2014 in which the Article 53(c) EPC objection was withdrawn, the appellant was of the opinion that the first examiner had obviously acted contrary to the Guidelines for Examination C-VIII, 1, 3rd paragraph, and had not discussed the case with the other members of the division. This could be derived from the introductory sentence of point 3.1 of the subsequent summons, which explained the change of mind to be the result of "thorough examination by all 3 members of the examining division". This objection is, however, purely speculative. Whether the change of mind was caused by the two other members of the division having their first say in the case or rather by a change of mind of the whole division cannot be established. In this context, the Board notes that points III.c and III.d of the decision point to an involvement of the whole division, which was initially "convinced ... that the method claims previously objected to were allowable ..." (point III.c) but then "re-evaluated all arguments on file and came to the conclusion that present method claims 1-11 and 18-21 did not fulfil the requirements of Article 53(c) EPC..." (point III.d). A change of mind - although surprising and in this case negative for the appellant - is neither forbidden by the EPC nor is it a substantial procedural violation.
2.3 Alleged violation of the right to be heard
In the summons, the examining division argued that the method could result in bleeding of the affected tissue (point 3.1.1). Due to bleeding, germs could enter the blood vessels, which was considered a substantial health risk (point 3.1.3). As these arguments were part of the summons, the appellant was aware of that reasoning and had the opportunity to present its comments in the oral proceedings. The decision is - at least in part - again based on this line of argument (see point 1 of the decision for the bleeding argument and point 3 for the health risk entailed therewith). Furthermore, the argument cannot be considered a pure allegation. The division made explicit reference to paragraphs [0021] and [0027] of the application as filed, which mention the possible use of a haemostatic compound, which is indeed a very strong indication that bleeding may occur - even though annexes 1 and 2 argue against it.
Bleeding implies the possibility of germs entering the blood vessels. This has not been denied by the appellant. Germs entering the blood vessels can cause infections and thus entail a certain health risk. If that health risk were substantial, a refusal of the method under Article 53(c) EPC in accordance with G 1/07 would be justified. There is thus at least one complete line of argument of which the appellant was aware and on which it could present its comments.
Whether this health risk is substantial or not is a question of judgement. The present Board agrees with the appellant (see point 1 above) that the health risk is indeed minor and not "substantial" in the sense of G 1/07. The examining division's decision thus suffers from an "error in judgement". Such errors in judgement do not constitute, however, a substantial procedural violation.
The decision further takes the appellant's submissions and arguments into account in that it argues (reasons, point 1, penultimate paragraph) - referring to decision T 5/04 - that even if the method were atraumatic (as advocated in annexes 1 and 2), a surgical method could be present. While these arguments appear not to be satisfactory, let alone convincing to the appellant, they still show that the division did indeed react to the submissions.
The appellant has argued that it only became aware of the division's argument, according to which it was not proven by the appellant that the statements and information provided in annexes 1 and 2 pertained to the subject-matter of claim 1, in the decision and thus could not present its comments. As pointed out in the summons, the Board has no way of ascertaining whether this argument was indeed not discussed during the oral proceedings. However, in view of the reasoning discussed above regarding bleeding and the health risk involved therewith, any procedural violation with respect to a further argument or line of argument would not have changed the result of the examination proceedings, the application having been refused already for the first reason. A potential procedural violation which is not causal to the decision cannot be considered substantial.
Therefore, the Board comes to the conclusion that there was no substantial procedural violation present.
2.4 No reimbursement of the appeal fee.
Without a substantial procedural violation there is no reason to reimburse the appeal fee.
3. Remittal to the department of first instance
The present decision exclusively dealt with objections under Article 53(c) EPC. The examining division had, however, already discussed with the appellant the other requirements of the EPC, in particular novelty and inventive step. Indeed, a rule 71(3) EPC communication was issued with respect to an auxiliary request only comprising the device claims. It is thus reasonable to remit the case to a division which is already familiar with the issues that remain to be discussed.
The Board further notes that although some unfortunate events have aggregated in the present case, there is no sign of the division being in any way biased or prejudiced against the appellant.
The case is thus remitted to the examining division for further prosecution in accordance with Article 111(1) EPC.
Order
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The case is remitted to the examining division for further prosecution.
3. The request for reimbursement of the appeal-fee is rejected.

03 April 2019

T 0280/15 - Cost apportionment

Key points

  • In this opposition appeal, the appellant (patentee) announced on the day before the oral proceedings, at 18:23, that it would not attend. The Board's preliminary opinion was negative for the patentee.
  • The Board orders the patentee to pay the costs for attending the oral proceedings, including 12 hours attorney time (at 250 EUR/hour, for an Italian attorney firm), as well as the travel and lodging costs. 


EPO T 0280/15 -  link



3. Kostenverteilung
3.1 Die Beschwerdegegnerin beantragte Kostenverteilung zu ihren Gunsten bezüglich Reise-, Unterbringungs-, Verpflegungs- und Mietwagenkosten, sowie für 12 Stunden in der Höhe von 250 EURO pro Stunde als Aufwandsentschädigung für die Vorbereitung des zugelassenen Vertreters.
3.2 Grundsätzlich trägt für die Verfahren vor dem EPA jede Partei ihre entstandenen Kosten selbst. Gemäß Artikel 104(1) EPÜ und Artikel 16(1)(c) VOBK kann auf Antrag jedoch die Kammer aus Billigkeitsgründen eine andere Kostenverteilung anordnen, für Handlungen oder Unterlassungen welche die rechtzeitige und effiziente Durchführung der mündlichen Verhandlung beeinträchtigen.

02 April 2019

T 0171/15 - Form refusal

Key point

  • Another refusal with Form 2061, another substantial procedural violation (three procedural violations this time: Rule 111(2), Article 113(1) and Article 113(2) EPC
  • " The decision under appeal expressly states that no submissions of the appellant were filed "in reply to the latest communication" - this being the communication dated 15 January 2014 (see point II above). However, this is not correct since the appellant had actually filed amended sets of claims together with a letter dated 4 April 2014, also comprising, inter alia, arguments in relation to Article 56 EPC. The board can therefore only conclude that the examining division failed to take the appellant's submissions of 4 April 2014 into account, thereby violating the appellant's right to be heard pursuant to Article 113(1) EPC." 
  • "   it might be assumed that the sets of claims filed on 4 April 2014 were the subject of the telephone conversation to which the appellant referred in its letter of 2 May 2014" 
  • So in this case, the Examiner discussed the set of claims filed on 4 April 2014 with the applicant in a phone call and the refusal decision still states explicitly that no amendments were filed in response to the Communication of 15 January 2014. In such a case, the Boards interpretation that the Examining Division "failed to take the appellant's submissions of 4 April 2014 into account" seems rather kind. In my view, it's more likely that the Examining Division was not aware of the requirements of a Form 2061 refusal, or did not care about it, and likely also did not read the actual text of the Form, or did not care about the statement contained therein that "the applicant filed no comments or amendments in reply to the latest communication" (which by the way is on the signature  page, so it are really three Examiner signing off on the statement). 

EPO T 0171/15 -  link


II. The decision under appeal was issued using EPO Form 2061 and reads:
"Grounds for the decision
In the communication(s) dated 15.01.2014, 18.09.2012 the applicant was informed that the application does not meet the requirements of the European Patent Convention. The applicant was also informed of the reasons therein.
The applicant filed no comments or amendments in reply to the latest communication but requested a decision according to the state of the file by a letter received in due time on 02.05.2014.
The application must therefore be refused."

Reasons for the Decision
Remittal of the case pursuant to Article 11 RPBA
1. Under Article 11 RPBA, the board remits a case to the department of first instance if fundamental deficiencies are apparent in the first instance proceedings, unless special reasons present themselves for doing otherwise.
2. In the board's judgement, the decision under appeal is deficient in various aspects, namely, for lack of proper reasoning within the meaning of Rule 111(2) EPC and in view of violations of the right to be heard under Article 113(1) EPC and of the principle laid down in Article 113(2) EPC, i.e. that the European Patent Office (EPO) must examine and decide upon a European patent application only in the text submitted to it, or agreed, by the applicant.